Related Experiment Video

Updated: Aug 31, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Rational therapeutic intervention in cancer: kinases as drug targets

Charles L Sawyers1

  • 111-934 Factor Building, University of California, Los Angeles Division of Hematology and Oncology, 10833 Le Conte Avenue, Los Angeles, California 90095-1678, USA. csawyers@mednet.ucla.edu

Current Opinion in Genetics & Development
|January 16, 2002
PubMed

Insights

New cancer drugs targeting specific genetic mutations show promise. Herceptin improved survival for HER2-positive breast cancer, and STI-571 benefited leukemia and GIST patients, spurring further kinase-inhibitor research.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Cancer treatment historically focused on broad chemotherapy.
  • Targeted therapies represent a paradigm shift in cancer treatment.
  • Specific molecular targets are crucial for effective drug development.

Purpose of the Study:

  • To report on landmark clinical studies of novel cancer drugs in 2001.
  • To highlight the efficacy of targeted therapies against specific cancer types.
  • To assess the impact of these findings on future cancer research.

Main Methods:

  • Clinical trials evaluating Herceptin, a monoclonal antibody targeting HER2/neu.
  • Clinical trials assessing STI-571, a small molecule kinase inhibitor.
  • Analysis of patient survival and clinical response rates in targeted cancer groups.

Main Results:

  • Herceptin demonstrated prolonged survival in women with HER2-positive metastatic breast cancer when combined with chemotherapy.
  • STI-571 produced significant clinical responses in patients with Bcr-Abl positive chronic myeloid leukemia.
  • STI-571 also showed efficacy in patients with c-kit positive gastrointestinal stromal tumors.

Conclusions:

  • Targeted therapies like Herceptin and STI-571 offer effective treatment options for specific cancers.
  • These successes validate the kinase-inhibitor approach for cancer therapy.
  • The findings have stimulated broader research into kinase-inhibitor applications for various cancers.

More Related Videos

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: